Moderna

NASDAQ:MRNABiotech

Cambridge, Massachusetts, United States · Est. 2010 · 2,500 employees

Moderna is a biotechnology company that develops mRNA-based therapeutics and vaccines for infectious diseases, oncology, and rare diseases.

Pipeline Programs↗

Distinct drugs in development (Preclinical–Phase 3)

Indications↗

Distinct diseases across all programs

100

Clinical Trials↗

All sponsored trials (all statuses)

Pipeline

Pipeline Snapshot

By Phase

24 drugs in development

Approved2

Phase 32

Phase 23

Phase 117

Preclinical2

By Therapeutic Area

top 5

Infectious Disease

1037%

Oncology

830%

Neurology

14%

Cardiovascular

14%

Nephrology

14%

R&D Momentum

57/100

Pipeline Velocity

22/100

Trial Completion Rate

90/100

Pipeline Concentration

28/100

Pipeline Freshness

68/100

Strategic Signals

↗Active in Neurology but thin pipeline — potential licensing opportunity

Activity

Recent Activity

Last 14 days

Jul 8, 2026

Completed

A Phase 3b/4, Open-label Study to Evaluate the Immunogenicity and Safety of mRNA-1283 COVID-19 Variant-containing Vaccine Formulations

Earlier

Jun 30, 2026TrialA Phase 1/2, Open-label, Multicenter Study of mRNA-2808 in Participants With Relapsed or Refractory Multiple Myeloma

Jun 27, 2026TrialA Phase 1, Randomized, Observer-blind, Placebo-controlled, Age De-escalation Study of the Safety, Tolerability, and Immunogenicity of mRNA-1345 and mRNA-1365 in Participants Aged 5 Months to <24 Months

Jun 24, 2026TrialPhase 1/2 Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors

Mar 17, 2026TrialA Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189 in Healthy Adults 18 to 30 Years of Age

Nov 26, 2025TrialA Study to Evaluate the Efficacy and Safety of mRNA-1283 and mRNA-1273 in Participants 50 to 64 Years of Age Without High-Risk Conditions for Severe Coronavirus Disease 2019 (COVID-19)

Aug 5, 2025TrialA Study of mRNA-1345 Following a Primary Dose of a Licensed Protein Subunit Respiratory Syncytial Virus (RSV) Vaccine in Adult Participants ≥60 Years of Age

Apr 16, 2025TrialA Study to Investigate Multiple Sclerosis Relapse Prevention With mRNA-1195 Compared With Placebo in Participants Aged 18 to ≤55 Years

4 more events

Mar 25, 2025TrialA Study of mRNA-4106 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Solid Tumors

Mar 7, 2025TrialA Study to Investigate the Immunogenicity, Reactogenicity, and Safety of mRNA-1083 (Influenza and COVID-19) Vaccine in Adults ≥18 to <65 Years of Age

Nov 18, 2024TrialStudy to Investigate the Immunogenicity, Reactogenicity, and Safety of mRNA-1083 Vaccine (SARS-CoV-2 [COVID-19] and Influenza) in Adults ≥50 Years of Age

Oct 31, 2024TrialA Study to Investigate Safety and Tolerability of mRNA-0184 Administered Subcutaneously in Healthy Participants

Details

Company Info

Company Overview

$25.0B

Mkt Cap

$5.0B

Revenue

—

Cash

CEOStephane Bancel

Founded2010

Employees2,500

HQCambridge, Massachusetts, United States

ExchangeNASDAQ:MRNA

Websitemodernatx.com

LinkedInCompany Page

Therapeutic Focus

Metabolic & EndocrineInfectious DiseaseNephrologyOtherImmunologyOncologyGastroenterologyCardiovascularHematologyOphthalmologyPsychiatryRespiratoryMusculoskeletalDermatologyNeurologyRare Disease

Pipeline

Drug Pipeline

Therapeutic Area

Preclinical

Phase 1

Phase 2

Phase 3

Approved

Cardiovascular(1 drug)

—

Cardiovascular(1 drug)

Infectious Disease(10 drugs)

—

Infectious Disease(10 drugs)

Nephrology(1 drug)

—

Nephrology(1 drug)

Neurology(1 drug)

—

Neurology(1 drug)

Oncology(8 drugs)

—

Oncology(8 drugs)

Unknown / Other(6 drugs)

—

Unknown / Other(6 drugs)

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)